Coverage for injectable weight loss medications depends almost entirely on your type of insurance, your state, and whether your doctor can tie the prescription to a qualifying medical condition. The two FDA-approved weight loss shots most people ask about are semaglutide (sold as Wegovy) and tirzepatide (sold as Zepbound), both of which belong to a class of drugs called GLP-1 receptor agonists. Despite widespread demand, the insurance landscape for these medications remains a patchwork of exclusions, restrictions, and slow-moving policy changes that leaves most people paying steep out-of-pocket costs or going without.
The FDA-Approved Injectable Options
Two injectable medications currently carry FDA approval specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Semaglutide 2.4 mg (Wegovy), approved in 2021, was the first GLP-1 receptor agonist cleared for weight loss. Tirzepatide (Zepbound), approved in late 2023, works on both GLP-1 and GIP receptors and has shown somewhat larger average weight loss in clinical trials. Both are self-administered weekly injections and are intended for long-term use alongside diet and exercise changes.
It is worth distinguishing these from their diabetes-labeled siblings. Semaglutide is also sold as Ozempic (at lower doses, for type 2 diabetes), and tirzepatide is sold as Mounjaro (also for diabetes). The diabetes versions are often easier to get covered because insurers have long recognized diabetes as a treatable medical condition. Some doctors prescribe the diabetes-labeled version off-label for weight loss, though insurers have become savvier at flagging this. Liraglutide (Saxenda), an older daily GLP-1 injection approved for weight loss in 2014, is still available but produces more modest results and has largely been overshadowed by the newer weekly options.
Why Medicare Does Not Cover Weight Loss Drugs
If you are on Medicare, the short answer is that Part D does not cover any medication prescribed for weight loss. When the Medicare Part D drug benefit was created, drugs for weight loss were explicitly excluded from coverage because the medications available at that time had limited effectiveness and unfavorable safety profiles, and obesity treatment was broadly perceived as cosmetic rather than medical.1PubMed Central. Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform That exclusion was written into the statute, and it has never been updated despite the arrival of far more effective and safer medications.
There is one narrow exception. In March 2024, Wegovy received an additional FDA indication for reducing the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. Because that indication is cardiovascular rather than weight-related, some Medicare Part D plans have begun covering Wegovy specifically for heart risk reduction, not for weight loss. In practice, this means your doctor needs to document that the prescription is for cardiovascular protection and that you meet the clinical criteria. Even then, coverage is not guaranteed and depends on your specific Part D plan’s formulary decisions.
Legislation called the Treat and Reduce Obesity Act, or TROA, has been circulating in Congress for over a decade with bipartisan support. It would lift Medicare’s statutory ban on weight loss drug coverage and expand access to comprehensive obesity treatment for older adults.2Innovation in Aging. Bridging the Gap in Obesity Treatment for Older People: The Role of the Treat and Reduce Obesity Act (TROA) As of mid-2025, the bill has not passed. The main sticking point is cost: the Congressional Budget Office has estimated that covering these drugs for all eligible Medicare beneficiaries would cost tens of billions of dollars over the next decade.
Medicaid Coverage Varies Dramatically by State
Medicaid is administered state by state, which means coverage for weight loss medications depends on where you live. A study examining Medicaid programs across the country found that only 16 states covered obesity pharmacotherapy, and that number showed no net increase between the two plan years studied. By contrast, the number of states covering nutritional counseling for obesity more than doubled, rising from 9 to 21, and bariatric surgery coverage grew from 45 to 49 states.3PubMed. Coverage for Obesity Prevention and Treatment Services: Analysis of Medicaid and State Employee Health Insurance Programs The pattern tells a clear story: state Medicaid programs have been more willing to pay for surgery and counseling than for weight loss drugs.
Even in states where Medicaid technically covers obesity medications, the formulary may not include the newest GLP-1 injectables. A state might cover an older, cheaper option like orlistat or naltrexone-bupropion but exclude Wegovy and Zepbound. And coverage that exists on paper often comes with layers of prior authorization, step therapy requirements (you have to try cheaper drugs first and fail before the insurer approves the one your doctor actually wants), and periodic re-authorization that can interrupt treatment. If you are on Medicaid, the most reliable way to find out what is covered is to call your managed care plan directly or ask your prescribing doctor’s office to run a benefits check.
Employer and Marketplace Plans
Commercial insurance through an employer or the Affordable Care Act marketplace is where coverage is most uneven and least predictable. An analysis of marketplace health insurance plans found that only about 11% had any coverage for FDA-approved obesity medications, spread across just nine states. Medicare policy was confirmed as a strict exclusion, and only seven state Medicaid programs carried drug coverage at the time of the analysis.4PubMed Central. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity Those numbers have improved somewhat since the newer drugs arrived, but the overall picture remains one of limited access.
Large self-insured employers, which include most Fortune 500 companies, make their own formulary decisions. Some have added GLP-1 coverage for weight loss because they see long-term savings from reduced diabetes, cardiovascular disease, and joint problems among their workforce. Others have explicitly excluded these drugs or added them and then pulled coverage after costs ballooned. Mid-size and small-group plans tend to follow whatever the insurer’s standard formulary offers, and many standard formularies still classify weight loss medications as non-essential or elective.
When commercial plans do cover weight loss shots, they almost always require prior authorization. Research on the prior authorization process for obesity drugs found that it can actually improve both medication compliance and behavioral compliance among patients who make it through the approval process, likely because the extra documentation ensures the prescribing doctor and patient are both invested in a comprehensive treatment plan.5PubMed. Does prior authorization of sibutramine improve medication compliance or weight loss? That said, prior authorization is a genuine barrier. It can take days to weeks, requires clinical documentation of body mass index, weight-related conditions, and often proof of failed attempts at other treatments, and the request may still be denied.
What Coverage Actually Looks Like in Practice
Getting an insurance company to approve a weight loss injection is only the first hurdle. Even with coverage, your copay or coinsurance can be substantial. Wegovy and Zepbound carry list prices above $1,000 per month, and depending on your plan’s tier placement, you might owe anywhere from $25 to several hundred dollars per fill. Plans that place these drugs on a specialty tier often require coinsurance (a percentage of the drug’s cost) rather than a flat copay, which can mean $200 to $400 or more out of pocket each month even with “coverage.”
Manufacturer savings cards exist for both Wegovy and Zepbound and can reduce costs significantly for people with commercial insurance. These cards typically bring the out-of-pocket cost down to $0 to $25 per month for eligible patients, but they come with conditions: they usually do not work if you have government insurance (Medicare, Medicaid, Tricare), and they expire after a set period or dollar cap. Once the savings card runs out, you are back to whatever your insurance actually covers.
Duration of coverage is another real concern. These medications are meant to be taken long-term, potentially indefinitely, because weight tends to return when the drug is stopped. Some insurers approve coverage for a set period, such as 12 or 24 months, and then require re-authorization or discontinue coverage entirely. A qualitative study exploring the impact of an insurance company cutting coverage for all anti-obesity medications found that patients experienced feelings of hope replaced by hopelessness, anger over what they perceived as unjust treatment, and a strong sense that the healthcare system and insurance company were stigmatizing their condition.6Obesity Pillars. Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication The emotional toll of gaining access, losing weight, and then losing coverage mid-treatment is a recurring theme in patient communities.
The Cardiovascular Backdoor
Wegovy’s FDA-approved cardiovascular indication has opened a door that is worth understanding. Because the drug is now approved not just for weight loss but also for reducing the risk of heart attack, stroke, and cardiovascular death in people with established heart disease and obesity, some insurers that exclude weight loss drugs will cover Wegovy when it is prescribed for cardiovascular risk reduction. This applies to some Medicare Part D plans, some commercial plans, and even some Medicaid programs that would otherwise say no.
The practical effect is that your chances of getting coverage improve considerably if you have documented cardiovascular disease in addition to obesity. Your doctor would need to submit the prescription with the cardiovascular indication, not the weight management indication, and the documentation needs to support it. If you have a history of heart attack, stroke, or peripheral artery disease along with a BMI over 27, this pathway is worth discussing with your physician. It is not a loophole exactly, since the FDA approval is legitimate, but it is a workaround that the insurance system’s rigid classification of “weight loss” as non-essential makes necessary.
Why Insurers Are Reluctant
The resistance to covering weight loss injections is fundamentally about money, and cost-effectiveness analyses help explain the math insurers are doing. A study modeling the lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in U.S. adults found that both drugs produced meaningful gains in quality-adjusted life years compared to no treatment, with tirzepatide showing the largest gains. However, at current prices, the cost per quality-adjusted life year was roughly $197,000 for tirzepatide and about $468,000 for semaglutide. To reach a widely used cost-effectiveness threshold of $100,000 per quality-adjusted life year, tirzepatide would need a price cut of about 30%, and semaglutide would need a cut of roughly 82%.7JAMA Health Forum. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
A separate cost-effectiveness analysis comparing several GLP-1 receptor agonists for obesity treatment found that semaglutide was the most effective in terms of weight loss among the drugs studied, with a cost-effectiveness ratio of about $135,000 per quality-adjusted life year when compared against the least expensive option in the analysis.8PubMed Central. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting Even under favorable assumptions, these drugs remain expensive relative to the value thresholds that insurers and policymakers use to decide what should be covered. The drugs work well. They are just priced at a level that makes universal coverage financially daunting, especially given the enormous number of Americans who would be eligible.
Insurers are also contending with a demand curve unlike anything they have seen with other chronic disease drugs. An estimated 40% of American adults meet the clinical criteria for obesity. If even a fraction of them started a $1,000-per-month injectable, the aggregate cost to any plan would be enormous. This is partly why so many plans have added step therapy, prior authorization, and periodic re-authorization requirements: they are trying to manage the volume of approvals rather than denying the drug category outright.
Compounded Versions and Why People Turn to Them
The combination of limited insurance coverage, high list prices, and ongoing drug shortages has pushed many people toward compounded versions of semaglutide and tirzepatide. Compounding pharmacies can legally produce copies of drugs that are on the FDA’s drug shortage list, and both semaglutide and tirzepatide have been on that list for extended periods. These compounded versions are typically sold at a fraction of the brand-name price, often $200 to $500 per month through online telehealth platforms.
The trend has raised significant safety concerns. An analysis described the global rise in compounded weight loss medicines as worrisome, noting that the shortage of brand-name drugs, exponential demand, and the fact that injectable weight loss drugs are often not covered by insurance are all driving people toward online pharmacies offering compounded alternatives.9PubMed Central. Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend The risks include inconsistent dosing, sterility problems, and the use of salt forms of semaglutide (like semaglutide sodium) that have not been tested in clinical trials the way the branded versions have. The FDA has warned consumers about potential safety issues with compounded GLP-1 products, and as the brand-name shortages resolve, the legal basis for compounding these drugs narrows.
If you are considering a compounded version because your insurance will not cover the brand-name drug, the key thing to understand is that you are trading regulatory oversight for affordability. Some compounding pharmacies are state-licensed and follow rigorous quality standards. Others operate in a gray zone. There is no easy way for a consumer to tell the difference without checking whether the pharmacy holds proper licensing and whether it is registered with the FDA as a 503B outsourcing facility, which subjects it to more oversight than a traditional compounding pharmacy.
Practical Steps to Improve Your Chances of Coverage
If you want your insurance to cover a weight loss injection, the process usually starts well before the prescription is written. Here are the steps that tend to matter most:
- Check your formulary first: Call your insurance company or log into your plan’s online portal and search for Wegovy, Zepbound, or Saxenda by name. If the drug is not on the formulary at all, prior authorization is unlikely to succeed. If it is listed but on a high tier, expect a higher copay but a better shot at approval.
- Document everything: Insurers want to see a BMI over 30 (or over 27 with a weight-related condition like type 2 diabetes, high blood pressure, or sleep apnea), a history of trying other approaches first (diet, exercise, sometimes older medications), and clear medical necessity from your doctor.
- Ask about the cardiovascular indication: If you have established heart disease and meet the criteria, Wegovy prescribed for cardiovascular risk reduction may be covered even when weight loss drugs are excluded from your plan.
- Appeal denials: A first-round denial is common and not necessarily the end. Many plans have an internal appeals process and then an external review option. Ask your doctor’s office to submit a letter of medical necessity and any supporting clinical records with the appeal.
- Use manufacturer savings programs: If you have commercial insurance, the manufacturer’s savings card can reduce your out-of-pocket cost dramatically while your coverage is active. These are separate from insurance approval and can often be stacked on top of your plan’s coverage.
How Coverage Is Shifting
The insurance landscape for weight loss shots is moving, just slowly. Several large employers added GLP-1 coverage between 2023 and 2025, and some pulled it back after seeing costs spike. State legislatures in a handful of states have introduced bills that would require insurers to cover FDA-approved obesity medications, though few have passed into law. The federal TROA bill, if it eventually clears Congress, would be the single biggest change by opening Medicare Part D to weight loss drug coverage for the first time.
Research tracking GLP-1 prescriptions has shown that prescription volume for weight loss rises substantially in plans that add coverage, which is both the promise and the problem.10JAMA Health Forum. GLP-1 Prescriptions for Weight Loss by Differences in Insurance Plan Coverage When people can afford the drugs, they use them. When they cannot, demand does not disappear; it just migrates to compounded alternatives, off-label prescriptions, or simply goes unmet. The policy tension between treating obesity as a legitimate chronic disease and managing the budget impact of doing so is unresolved, and it is unlikely to be settled quickly. For now, coverage remains plan-specific, diagnosis-dependent, and worth fighting for if you and your doctor believe the medication is appropriate for your health.